bioMérieux : One can take advantage of the trading range to enter new positions
Entry price | Target | Stop-loss | Potential |
---|
€96.05 |
€106 |
€92 |
+10.36% |
---|
After having been stuck in a trading range, shares in bioMérieux are returning to the lower bound of the range phase. This appears to be a good opportunity for opening new positions.
Summary● The company has strong fundamentals. More than 70% of companies have a lower mix of growth, profitability, debt and visibility.
● The company has a good ESG score relative to its sector, according to Refinitiv.
Strengths● The company is in a robust financial situation considering its net cash and margin position.
● The average price target of analysts who are interested in the stock has been strongly revised upwards over the last four months.
Weaknesses● The company benefits from high valuations in earnings multiples.
● The company is highly valued given the cash flows generated by its activity.
● The company is not the most generous with respect to shareholders' compensation.
● For the last few months, analysts have been revising downwards their earnings forecast.
● The overall consensus opinion of analysts has deteriorated sharply over the past four months.
The content herein constitutes a general investment recommendation, prepared in accordance with provisions aimed at preventing market abuse by Surperformance, the publisher of MarketScreener.com. More specifically, this recommendation is based on factual elements and expresses a sincere, complete, and balanced opinion. It relies on internal or external data, considered reliable as of the date of their release. Nevertheless, this information, and the resulting recommendation, may contain inaccuracies, errors, or omissions, for which Surperformance cannot be held responsible. This recommendation, which in no way constitutes investment advice, may not be suitable for all investor profiles. The reader acknowledges and accepts that any investment in a financial instrument involves risks, for which they assume full responsibility, without recourse against Surperformance. Surperformance commits to disclosing any conflict of interest that may affect the objectivity of its recommendations.
Surperformance is Buy on BIOMÉRIEUX since 27/07/2023
.